Evidence map›Paper›PMID 42814605›Full record

ArticleBriefings in bioinformatics2026

MMP2Mol: a matched molecular pairs-based framework for ligand-based de novo drug design.

Dekun Chen, Hui Li, Jianwang Liu, Yueping Jiang, Dongsheng Cao, Shao Liu

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dekun ChenDepartment of Pharmacy, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Kaifu District, Changsha, Hunan 410008, China.
Hui LiXiangya School of Pharmaceutical Sciences, Central South University, No. 172 Tongzipo Road, Yuelu District, Changsha, Hunan 410013, China.
Jianwang LiuDepartment of Pharmacy, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Kaifu District, Changsha, Hunan 410008, China.
Yueping JiangDepartment of Pharmacy, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Kaifu District, Changsha, Hunan 410008, China.
Dongsheng CaoXiangya School of Pharmaceutical Sciences, Central South University, No. 172 Tongzipo Road, Yuelu District, Changsha, Hunan 410013, China.ORCID 0000-0003-3604-3785
Shao LiuDepartment of Pharmacy, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Kaifu District, Changsha, Hunan 410008, China.ORCID 0000-0002-0576-8698

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Designing target-relevant molecules is particularly difficult when only limited bioactivity data are available. We present MMP2Mol, a ligand-based generative framework that combines matched molecular pair (MMP) analysis with a pretrained chemical language model (CLM). MMP2Mol extracts target-specific structure-activity transformations from available ligands, applies the prioritized transformations to construct a virtual focused library, and fine-tunes the CLM toward target-relevant chemical space. The framework was evaluated across ten therapeutic targets and compared with direct CLM fine-tuning, Seq2Seq, and Reinvent 4. In repeated experiments on F2, BRD4, and PARP1, MMP2Mol achieved 92.8%-95.3% validity and 99.5%-99.7% uniqueness. When both methods were evaluated against the same original active-compound reference, molecular novelty increased from 57.8%-64.0% for the CLM baseline to 79.8%-82.0% for MMP2Mol, while internal diversity remained broadly comparable. The gains were most evident for F2 and BRD4, whereas performance varied across the smaller target datasets. These findings indicate that MMP-derived chemical knowledge can improve the focus and reproducibility of ligand-based molecular generation under limited-data conditions. MMP2Mol therefore provides a practical strategy for computational candidate generation and prioritization in early-stage drug discovery.

Indexed as

Drug DesignBromodomain Containing ProteinsCell Cycle ProteinsHumansLigandsPoly (ADP-Ribose) Polymerase-1Structure-Activity RelationshipTranscription FactorsBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsLigandsPoly (ADP-Ribose) Polymerase-1Transcription Factorschemical language models (CLMs)data-scarce drug discoveryligand-based drug designmatched molecular pair (MMP)structure–activity relationship (SAR)

Identifiers

PMID42814605
PMCPMC13625653

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.